Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05539872
Other study ID # API-I004-CL-B
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date August 22, 2022
Est. completion date January 30, 2023

Study information

Verified date January 2024
Source Amphastar Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, double-blinded, two-treatment, two-period, two-sequence crossover pivotal Biosimilar study. The purpose of this study is to establish pharmacokinetic (PK) and pharmacodynamics (PD) biosimilarity of proposed biosimilar I004 and the US-approved NovoLog.


Recruitment information / eligibility

Status Completed
Enrollment 69
Est. completion date January 30, 2023
Est. primary completion date January 29, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Upon review, agree to participate and sign informed consent. - Healthy male and female subjects = 18 to = 65 years of age. - Body mass index (BMI) = 18.5 to = 29.9 kg/m2 - Weight = 50 kg. - Fasting plasma glucose of < 100 mg/dL (5.5 mmol/L) measured with YSI at site; one repeat test is allowed. - HbA1c < 5.7%. - Non-smoker for = 3 months prior to Screening. - Female candidates must be > 1 year post-menopausal, surgically sterile, or practicing a clinically acceptable form of birth control and confirmed by negative serum pregnancy test at Screening. Exclusion Criteria: - History of diabetes mellitus. - Resting blood pressure (BP) > 140/90 mmHg or < 90/60 mmHg. Subjects BP may be re-checked. - Participation in an investigational drug/device study within 30 days or 5 half-lives within the last dose of any study drug, whichever is longer. - History of any serious adverse reaction or hypersensitivity to any of the investigational product components. - Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or abnormalities, or other major systemic disease that, according to the investigator, would unduly risk the subject's safety or may impact the conduct of the study. - Subject shows evidence of significant active neuropsychiatric disease, including taking prescription medication for such diseases (including anti-depressant/anti-anxiety medication). - Presence of clinically significant physical, laboratory, or ECG findings at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results, or may present a safety issue to that particular subject (laboratory results may be re-checked once on a separate day per Investigator discretion). - Long QT syndrome or family history of long QT syndrome or corrected QT interval (QTcF) > 450 ms in men, > 470 ms in women at Screening. - Liver function test results of AST and/or ALT = 2.5 upper normal limit (ULN) - Subject has a history of syncope. - History of any major surgery within 6 months. - History of any active infection, other than mild viral illness within 30 days prior to dosing. - History of blood clots (e.g., deep vein thrombosis or embolism) or a frequent appearance in 1st degree relatives as judged by the Investigator. - Known history or positive test of hepatitis B surface antigen (HBsAG), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2) antibody. - History of alcohol abuse as judged by the Investigator within approximately 1 year. Average weekly alcohol intake > 21 units/week (males) and > 14 units/week (females) or are unwilling to stop alcohol consumption from 24 hours prior to each dosing until discharged from the clinical research unit (CRU). Positive alcohol test at Screening. (One unit of alcohol equals about 250 mL of beer or lager, one glass of wine, or 20 mL of spirits). - History of illicit drug abuse, including marijuana, within approximately 1 year or evidence of current use as judged by the Investigator. Positive drug test at Screening. - Donation or loss of > 500 mL of blood within 56 days. - Chronic use of over-the-counter or prescription medication within 7 or 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, or birth control methods [Desogestrel is not allowed]). - Unable to comply with the safety monitoring requirements of this clinical study or is considered by the investigator to be an unsuitable candidate for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
I004
Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
NovoLog
Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.

Locations

Country Name City State
United States Amphastar Study Site Chula Vista California

Sponsors (1)

Lead Sponsor Collaborator
Amphastar Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Serum Insulin Aspart Concentration, CIAmax Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart From 60 minutes before dose until 12 hours after dose
Primary Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to 12 hours post-dose, AUCIA(0-12h) Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. AUCIA(0-12h) will be calculated from the concentration curves. From 60 minutes before dose until 12 hours after dose
Primary Maximum Serum Human Insulin Concentration, CHImax Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Human Insulin From 60 minutes before dose until 12 hours after dose
Primary Area Under the Curve (AUC) of Human Insulin Serum Concentration from time 0 to 12 hours post-dose, AUCHI(0-12h) Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Human Insulin. AUCHI(0-12h) will be calculated from the concentration curves. From 60 minutes before dose until 12 hours after dose
Primary Maximum Glucose Infusion Rate, Gmax Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Primary Area Under the Curve (AUC) for Glucose Infusion Rate from time 0 to 12 hours post-dose, AUCG(0-12h) Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. AUCG(0-12h) will be calculated from the glucose infusion rate curves. From drug administration until 12 hours after dose
Secondary Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to infinity, AUCIA(0-8) Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. AUCIA(0-8) will be calculated from the concentration curves. From 60 minutes before dose until 12 hours after dose
Secondary Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to 2 hours post-dose, AUCIA(0-2h) Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. AUCIA(0-2h) will be calculated from the concentration curves. From 60 minutes before dose until 2 hours after dose
Secondary Time of Maximum Insulin Aspart Serum Concentration, tIAmax Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. From 60 minutes before dose until 12 hours after dose
Secondary Apparent Clearance of Insulin Aspart, CL/F Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. From 60 minutes before dose until 12 hours after dose
Secondary Apparent Volume of Distribution of Insulin Aspart, Vz/F Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. From 60 minutes before dose until 12 hours after dose
Secondary Half-life of Insulin Aspart, t1/2 Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Insulin Aspart. From 60 minutes before dose until 12 hours after dose
Secondary Time of Maximum Human Insulin Serum Concentration, tHImax Pharmacokinetic (PK) blood samples will be collected starting 60 minutes before dose and until 12 hours after dose. Serum will be isolated for analyzing the concentrations of Human Insulin. From 60 minutes before dose until 12 hours after dose
Secondary Area Under the Curve (AUC) for Glucose Infusion Rate due to Insulin Aspart from time 0 to 12 hours post-dose, AUCGA(0-12h) Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. AUCGA(0-12h) will be calculated from the glucose infusion rate curves. From drug administration until 12 hours after dose
Secondary Maximum Glucose Infusion Rate due to Insulin Aspart, GAmax Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Secondary Area Under the Curve (AUC) for Glucose Infusion Rate (GIR) from time 0 to the Time of Last Measureable GIR, AUCG(0-last) Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. AUCG(0-last) will be calculated from the glucose infusion rate curves. From drug administration until 12 hours after dose
Secondary Area Under the Curve (AUC) for Glucose Infusion Rate from time 0 to 2 hours post-dose, AUCG(0-2h) Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. AUCG(0-2h) will be calculated from the glucose infusion rate curves. From drug administration until 2 hours after dose
Secondary Last Measureable Glucose Infusion Rate, Glast Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Secondary Time of Maximum Glucose Infusion Rate, tGmax Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Secondary Time of Glucose Infusion Start, tGonset Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Secondary Time of Last Measureable Glucose Infusion Rate, tGlast Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Secondary Time to Half of Maximum Glucose Infusion Rate (Gmax) Before Gmax Is Reached, tG50%early Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
Secondary Time to Half of Maximum Glucose Infusion Rate (Gmax) After Gmax Is Reached, tG50%late Participants will undergo a euglycemic clamp, where blood glucose concentration will be held at a constant target level by adjusting exogenous glucose infusion rate (GIR) following drug administration. GIR will be recorded for the duration of the euglycemic clamp and used to evaluate the Pharmacodynamic (PD) response. From drug administration until 12 hours after dose
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1